SCHEMBL1852565

SCHEMBL1852565

O=C(O)c1cccc(-c2cccc3nn(Cc4ccccc4F)cc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.49
KDM5A P29375 2/20 0.46
KDM5B Q9UGL1 2/20 0.46
KDM4A O75164 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
ATM Q13315 1/20 0.44
MAOA P21397 1/20 0.44
BLVRB P30043 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
FABP3 P05413 1/20 0.42
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
FOLH1 Q04609 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851796 0.86 GPR52 (0.47) GPR52SMN1; SMN2TSHRL3MBTL1KMT2A
SCHEMBL3211059 0.85 GPR52 (0.57) GPR52HDAC6FABP3FABP4FABP5
SCHEMBL1851132 0.85 GPR52 (0.68) GPR52HDAC6L3MBTL1
SCHEMBL1852543 0.84 GPR52 (0.54) GPR52MAOABLVRBHDAC6NPC1
SCHEMBL1850248 0.84 GPR52 (0.54) GPR52KDM5AKDM5BKDM4AKDM4C
SCHEMBL1849911 0.83 GPR52 (0.58) GPR52KDM5AKDM5BKDM4CNPC1
SCHEMBL1850927 0.82 GPR52 (0.55) GPR52HDAC6L3MBTL1KMT2A
SCHEMBL1854577 0.82 GPR52 (0.52) GPR52NPC1RAB9ASMN1; SMN2CASP3
SCHEMBL1848441 0.80 GPR52 (0.50) GPR52FABP3FABP4FABP5NPC1
SCHEMBL1850808 0.79 GPR52 (0.55) GPR52KDM4CNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885KDM5A 2482/4885KDM5B 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.